2022 Volume 17 Issue 4 Pages 147-152
When continuous subcutaneous injection of opioid analgesics is initiated for patients in the terminal stages of cancer who are unable to take oral medication, Haloperidol is widely used in combination to prevent nausea and vomiting. However, Haloperidol carries the risk of skin damage at the site of subcutaneous injection. Therefore, we tried to use Blonanserin patch for the prevention of nausea and vomiting during continuous subcutaneous injection of Hydromorphone hydrochloride. In the present study, we retrospectively evaluated patients who had no history of opioid analgesic use, no concomitant use of other antiemetic drugs or antipsychotics, and who were followed up for at least 1 week. In the 5 patients who used Blonanserin patch, no nausea or vomiting occurred, and there were no skin lesions at the site of Blonanserin patch application or subcutaneous injection. In 5 cases of Haloperidol with continuous subcutaneous injection, 1 patient had nausea, 2 had skin lesions at the subcutaneous puncture site. Blonanserin patch seemed to be an option for the prevention of nausea and vomiting during continuous subcutaneous injection of Hydromorphone hydrochloride in end-stage cancer patients who were hospitalized in a palliative care unit and were unable to take oral medication.
